Kit capable of detecting expression quantity of BAALC (brain and acute leukemia cytoplasmic) gene mRNA (Messenger Ribose Nucleic Acid)

Abstract

The invention discloses a kit capable of detecting expression quantity of BAALC (brain and acute leukemia cytoplasmic) gene mRNA (Messenger Ribose Nucleic Acid), belonging to the field of biotechnology. The kit comprises a detection primer and fluorescence probe, a cDNA first strand synthesis reagent, fluorogenic quantitative PCR (Polymerase Chain Reaction) mixed liquor, negative control and positive control, wherein the primers and fluorescence probes for detection include a BAALC gene primer, a reference gene ABL primer and a Taqman fluorescence probe. The BAALC gene is a sign of progenitor cell of early hematopoietic cell, and is abnormally expressed in acute and chronic patients with AML (Acute Myelocytic Leukemia), ALL (Acute Lymphocytic Leukemia) and CML (Chronic Myeloid Leukemia). According to the embodiment of the invention, the mRNA level of the BAALC gene is detected by fluorogenic quantitative PCR with high sensitivity and specificity, and the specificity and sensitivity of the detection result are both obviously improved. The kit can provide a brandnew, fast, simple and convenient gene diagnosis technology for clinically evaluating the diagnosis, prognosis and reappearance period of acute lymphocytic leukemia.

Description

technical field [0001] The invention relates to the fluorescent quantitative PCR technology in the field of biotechnology, in particular to a kit for detecting the expression level of BAALC gene mRNA. Background technique [0002] Acute myeloid leukemia (AML) is a malignant clonal disease with clinical molecular heterogeneity and is the most common type of acute leukemia. Its treatment effect is poor, and the complete remission rate after chemotherapy is 60%-70% , with a median survival of approximately 2 years. In the United States, more than 11,900 new cases occur each year. Most AML patients are middle-aged and elderly. The average age of the patients is 65 years old, and less than 10% of the cases are children. About half of adult AML patients lack chromosomal aberrations, and although these patients have a longer prognosis, only 40% survive long-term. Molecular technology can accurately distinguish the risk level of patients, so as to improve the treatment effect. Th...

AI Technical Summary

Problems solved by technology

The probe hybridization method has a high false positive rate; the gene chip method is expensive and the preparation method is cumbersome; mass spectrometry is difficult to carry out in general medical institutions; although the gene sequencing method has high sensitivity and specificity, it is expensive and cumbersome to operate. time consuming

Although the specificity and sensitivity of immunohistochemical method are relatively high, real-time fluorescent quantitative PCR (Polymerase Chain Reaction, polymerase chain reaction) has stronger specificity and higher sensitivity than immunohistochemical method. It is fast and reduces pollution, but there is no report on the detection of BAALC gene in acute myeloid leukemia by real-time fluorescent quantitative PCR method

Images